文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

CheckMate 204中纳武利尤单抗联合伊匹木单抗治疗黑色素瘤脑转移患者的颅内缓解评估标准比较分析

Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204.
PubMed 文献 · J Clin Oncol · 2025-01-03

CheckMate 204研究探索性分析纳入119例至少一个未放疗黑色素瘤脑转移患者,接受纳武利尤单抗联合伊匹木单抗治疗后,用mRECIST、RANO-BM(5 mm和10 mm界值)及体积标准评估颅内客观缓解率。mRECIST和体积标准缓解率更高,且与颅内无进展生存和总生存相关性更强。分析支持mRECIST或仅影像学RANO-BM 5 mm作为黑色素瘤脑转移试验的可靠评估量表。

要点

  • mRECIST和体积标准评估的颅内客观缓解率高于RANO-BM或RECIST。
  • mRECIST和体积标准缓解与颅内无进展生存和总生存相关性更强。
  • 全部靶病灶<10 mm的患者中缓解可被准确判定。

核心结论

  • 本分析支持mRECIST或仅影像学RANO-BM 5 mm作为黑色素瘤脑转移试验的可靠评估量表。
  • 体积标准缓解与生存相关,支持其用于未来试验。
  • 全部黑色素瘤脑转移病灶<10 mm的患者中缓解可被准确判定,支持未来试验纳入黑色素瘤脑转移≥5 mm的患者。

研究设计与样本

  • CheckMate 204探索性分析纳入119例至少一个未放疗黑色素瘤脑转移患者。
  • 患者接受纳武利尤单抗联合伊匹木单抗每3周一次(共4剂),随后纳武利尤单抗每2周一次,最长24个月。
  • 采用盲法评估,使用mRECIST、RANO-BM(5 mm和10 mm界值)及体积标准(5 mm和10 mm)评估颅内客观缓解率。
  • 以6周缓解 Landmark 分析,比较缓解者与非缓解者的颅内无进展生存和总生存。

主要发现

  • mRECIST和体积标准评估的颅内客观缓解率高于RANO-BM或RECIST。
  • mRECIST和体积标准缓解与颅内无进展生存和总生存相关性更强。
  • mRECIST缓解但RANO-BM 5 mm非缓解者(n=14)的总生存与RANO-BM 5 mm缓解者(n=41)相似。
  • 临床恶化影响RANO-BM评估的颅内客观缓解率;仅影像学评估而不考虑临床恶化时,RANO-BM 5 mm表现与mRECIST相似。
  • 41例全部靶病灶<10 mm的患者中,缓解者的颅内无进展生存和总生存与总人群中缓解者相似,提示这些患者中缓解可被准确判定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In CheckMate 204, nivolumab + ipilimumab showed high intracranial (IC) objective response rates (icORRs) in patients with melanoma brain metastases (MBMs). Using icORR as a surrogate for overall survival (OS) has prompted use of alternate response criteria. To set the stage for harmonized MBM trials, the aim of this exploratory analysis was to determine icORR using several response criteria and examine correlations of response with survival. METHODS: Patients (N = 119) with ≥one unirradiated MBMs received nivolumab + ipilimumab every 3 weeks (four doses), followed by nivolumab every 2 weeks for ≤24 months. Blinded review icORR was assessed with modified RECIST (mRECIST), Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM; 5 mm and 10 mm cutoffs), and volumetric criteria (5 mm and 10 mm). Using a 6-week response landmark, IC progression-free survival (icPFS) and OS were compared for responders versus nonresponders. RESULTS: icORR was higher with mRECIST and volumetric criteria than with RANO-BM or RECIST. mRECIST and volumetric response also showed stronger correlations with icPFS and OS. mRECIST responders who were RANO-BM 5 mm nonresponders (n = 14) had similar OS to RANO-BM 5 mm responders (n = 41). Clinical deterioration affected RANO-BM icORR; however, when assessed only radiographically without deterioration, RANO-BM 5 mm performed similarly to mRECIST. Among 41 patients with target lesions all <10 mm, responder icPFS and OS were similar to those of responders in the total population, indicating that response could be accurately determined in these patients. CONCLUSION: This analysis supports mRECIST or radiographic-only RANO-BM 5 mm as reliable assessment scales in MBM trials. Volumetric response correlated with survival, supporting its application in future trials. Response could be accurately determined in patients with MBMs all <10 mm, supporting the inclusion of patients with MBMs ≥5 mm in future trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Huang RY, Youssef G, Nelson T, et al. Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. J Clin Oncol. 2025. PMID: 39752606. doi:10.1200/JCO.24.00953

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。